ArticleCancer control : journal of the Moffitt Cancer Center
Prognostic Impact of Combined Oral Contraceptive Use Among Ovarian Cancer Patients in Addis Ababa, Ethiopia: A Cohort Study.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionGlobally, ovarian cancer is the third most common gynecological malignancy, following cervical and uterine cancers. The protective effect of combined oral contraceptive (COC) use against the development of primary ovarian cancer is well-established. However, little is known about the potential prognostic benefit of COC use among patients already diagnosed with ovarian cancer. Therefore, this study aimed to evaluate the association of COC use on ovarian cancer survival in oncology centers in Addis Ababa, Ethiopia.MethodsA hospital-based, retrospective cohort study was conducted among a total of 436 ovarian cancer patients, comprising 109 COC users and 327 non-users. Kaplan-Meier survival curves and the log-rank test were used to assess differences in overall survival. The incidence density rate of mortality was calculated for each group. The effect of COC use on time to death following an ovarian cancer diagnosis was estimated using Cox proportional hazards regression, with a significance level of 5%.ResultsThe mortality incidence density rate among ovarian cancer patients with prior COC use was 5.55 per 1,000 person-years (95% CI: 3.69-8.35), compared with 13.95 per 1,000 person-years (95% CI: 11.89-16.35) among non-users. The 5-year overall survival rate was higher among COC users (66.18%; 95% CI: 53.07-76.41) than among non-users (37.65%; 95% CI: 31.26-44.01). The median overall survival time for the cohort was 49.80 months. After adjustment for potential confounders, prior COC use was associated with a lower hazard of mortality compared with non-use (adjusted hazard ratio [AHR] = 0.37; 95% CI: 0.24-0.59).ConclusionsIn the present study, prior COC use was associated with improved overall survival among women diagnosed with ovarian cancer. These findings provide preliminary evidence of a possible prognostic association; however, further studies are needed to confirm these findings and clarify the underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.